← Back to Search

NMDA Receptor Antagonist

Radiprodil for GRIN Disorders

Phase 1
Recruiting
Research Sponsored by GRIN Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (week 5) to study completion (average of 2 years).
Awards & highlights

Study Summary

This trial aims to test the safety and effectiveness of radiprodil for treating a specific genetic disorder in children. All participants will receive radiprodil in the initial phase of the study lasting up

Who is the study for?
This trial is for children aged 6 months to 12 years with GRIN gene variants causing overactive NMDA receptors. Participants must have frequent motor seizures or significant behavioral/motor symptoms despite previous treatments. They should be on stable seizure therapies during the study.Check my eligibility
What is being tested?
The trial tests Radiprodil's safety, tolerability, and potential effectiveness in treating GRIN-related disorders in kids. It's an open-label phase 1B study where all participants receive the drug, first in a six-month period (Part A), then possibly longer-term (Part B).See study design
What are the potential side effects?
As this is a phase 1B trial primarily assessing safety and tolerability, specific side effects of Radiprodil are not detailed here but may include typical drug reactions such as nausea, fatigue, allergic responses or other unforeseen issues related to its mechanism.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (week 5) to study completion (average of 2 years).
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (week 5) to study completion (average of 2 years). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (SAEs), TEAEs Leading to Discontinuation and Severity of TEAEs
Maximum Plasma concentration of radiprodil (Cmax)
Pharmacokinetic plasma concentration of radiprodil, Time corresponding to occurrence of Cmax (Tmax)
+3 more
Secondary outcome measures
Aberrant Behavior Checklist-Community (ABC-C)
Caregiver Burden Inventory (CBI)
Caregiver Global Impression of Change (CaGI-C)
+7 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: RadiprodilExperimental Treatment1 Intervention
Liquid suspension of radiprodil, at concentrations 0.25 mg/mL or 2.50 mg/mL for 1% and 10% formulation respectively. It will be administered twice a day (bid) either orally or via gastric or nasogastric tube, slowly up-titrated to the highest tolerated dose.

Find a Location

Who is running the clinical trial?

GRIN Therapeutics, Inc.Lead Sponsor
1 Previous Clinical Trials
30 Total Patients Enrolled
Vijay Rai, PhDStudy DirectorAssociate Director of Clinical Operations
Michael Panzara, MD, MPHStudy ChairChief Medical Officer
3 Previous Clinical Trials
3,715 Total Patients Enrolled
~12 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top